Navigation Links
Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
Date:5/2/2013

SAN DIEGO, May 02, 2013 /PRNewswire/ -- Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

(Logo: http://photos.prnewswire.com/prnh/20130502/LA06084LOGO)

"This collaboration leverages Abide's unique and innovative therapeutic engine," said Alan Ezekowitz , MBChB, D.Phil., President and CEO of Abide Therapeutics.  "We are eager to validate unique targets that we hope will lead to the development of novel therapeutics that will benefit patients with diabetes and metabolic diseases." 

Under the terms of the agreement, Abide Therapeutics is eligible to receive an upfront payment, research funding, and potential milestone payments for up to $430 million for three products. Further details of the financial terms were not disclosed. Merck will have worldwide commercialization rights to any products that may be developed as a result of the collaboration. Abide Therapeutics is entitled to receive royalty payments on global sales from any such products.

"Diabetes and related disorders continue to represent a significant global, unmet medical need," said Nancy Thornberry , Senior Vice President and Franchise Head, Diabetes and Metabolism, Merck Research Laboratories. "We look forward to working with Abide on the discovery and development of important new medicines."

About Serine Hydrolases

The large family of serine hydrolases are validated but largely under explored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases.  The technology provides a rapid and effective method for target identification and validation.  

About Abide Therapeutics

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger , that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas.  Abide is located in San Diego.  To learn more, visit www.abidetx.com


'/>"/>
SOURCE Abide Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
2. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
3. SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board
4. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
5. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
6. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
7. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
8. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
9. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
10. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
11. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- , , Marks E-QURE , ... distribution agreement, following similar agreements in Israel and ... 5 billion global market ... a leader in medical devices for the treatment of advanced wound care, announced ... (TeckMedica) in Colombia for the Company,s patented Bio-electrical Signal ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 The ... 1,669.40 billion by 2021 from USD 1,179.20 billion in ... period. Increasing prevalence of chronic diseases, increasing demand ... the factors driving the growth of this market. Whereas, ... and generic drugs offer significant growth opportunities for players ...
(Date:1/18/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Breast Imaging Technologies ... projects that the global breast imaging technologies market size was ... reach $4,502 million by 2022, growing at a CAGR of ... and Europe together accounted for ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, a division ... credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro Healthcare Staffing ... recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital Advisors provided ...
(Date:1/19/2017)... ... January 19, 2017 , ... Huntington Beach dental ... sleep apnea and TMJ disorders. These conditions are quite common particularly in midlife ... personalized care to reduce the risk of these consequences and improve overall wellbeing. ...
(Date:1/19/2017)... ... , ... Sam & Associates Insurance Agency, a full service firm providing asset ... Bay Area, is launching a charity drive to raise awareness of heart disease risk ... primary killer of adult men and women in America, and is responsible for over ...
(Date:1/19/2017)... ... January 19, 2017 , ... St. Catherine’s Village announced ... Siena Center is a skilled nursing facility on the grounds of the St. Catherine’s ... It recently was voted the best nursing home in Mississippi for the second year ...
(Date:1/19/2017)... ... January 18, 2017 , ... The CHP suggests that California ... rain storm by slowing down and increasing the space between themselves and other vehicles, ... based car accident attorney Raymond R. Hassanlou notes that, rain or shine, drivers should ...
Breaking Medicine News(10 mins):